Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Daniel H Whittam , Alvaro Cobo-Calvo , A Sebastian Lopez-Chiriboga , Santiago Pardo , Matthew Gornall , Silvia Cicconi , Alexander Brandt , Klaus Berek , Thomas Berger , Ilijas Jelcic , Grace Gombolay , Luana Micheli Oliveira , Dagoberto Callegaro , Kimihiko Kaneko , Tatsuro Misu , Marco Capobianco , Emily Gibbons , Venkatraman Karthikeayan , Bruno Brochet , Bertrand Audoin , Guillaume Mathey , David Laplaud , Eric Thouvenot , Mikaël Cohen , Ayman Tourbah , Elisabeth Maillart , Jonathan Ciron , Romain Deschamps , Damien Biotti , Kevin Rostasy , Rinze Neuteboom , Cheryl Hemingway , Rob Forsyth , Marcelo Matiello , Stewart Webb , David Hunt , Katy Murray , Yael Hacohen , Ming Lim , M Isabel Leite , Jacqueline Palace , Tom Solomon , Andreas Lutterotti , Kazuo Fujihara , Ichiro Nakashima , Jeffrey L Bennett , Lekha Pandit , Tanuja Chitnis , Brian G Weinshenker , Brigitte Wildemann , Douglas Kazutoshi Sato , Su-Hyun Kim , Saif Huda , Ho Jin Kim , Markus Reindl , Michael Levy , Sven Jarius , Silvia Tenembaum , Friedemann Paul , Sean Pittock , Romain Marignier , Anu Jacob Multiple Sclerosis and Related Disorders(2020)
摘要
•Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children.•Rituximab reduced relapse rates in MOG-IgG-associated disorder by 37%.•Compared to similar studies in AQP4-IgG-associated NMOSD, the efficacy seems lower.•Some patients relapsed despite apparent circulating B-cell depletion.
更多 查看译文
关键词
Myelin oligodendrocyte glycoprotein, MOG, Rituximab, Neuromyelitis optica, Optic neuritis
AI 理解论文
溯源树
样例